Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 8/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439431 | 1.00 | NR1H2 (0.43) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL1439345 | 1.00 | NR1H2 (0.43) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL7809158 | 1.00 | NR1H2 (0.43) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL7807938 | 1.00 | NR1H2 (0.43) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL16772779 | 0.89 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1902097 | 0.88 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL2522899 | 0.88 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL21466110 | 0.88 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL26791233 | 0.88 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL5397081 | 0.88 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167497-B2 | Stable NAD/NADH derivatives | ROCHE DIABETES CARE, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160326567-A1 | STABLE NAD/NADH DERIVATIVES | ROCHE DIAGNOSTICS GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326567-A1 | STABLE NAD/NADH DERIVATIVES | ROCHE DIAGNOSTICS GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9399790-B2 | Stable NAD/NADH derivatives | ROCHE DIABETES CARE, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399790-B2 | Stable NAD/NADH derivatives | ROCHE DIABETES CARE, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-8809013-B2 | Stable NAD/NADH derivatives | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809013-B2 | Stable NAD/NADH derivatives | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140206024-A1 | STABLE NAD/NADH DERIVATIVES | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206024-A1 | STABLE NAD/NADH DERIVATIVES | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20080213809-A1 | Coenzyme substrates; kits; nicotinamide adenine dinucleotide; biochemical detection | ROCHE DIABETES CARE, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080213809-A1 | Coenzyme substrates; kits; nicotinamide adenine dinucleotide; biochemical detection | ROCHE DIABETES CARE, INC. | 2008-09-04 | — | — | US | disclosed |
| US-6372914-B1 | Intermediates useful for the manufacture of carbapenem and a stereoselective manufacturing method therefor | EISAI CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0528678-B1 | A pyrrolidylthiocarbapenem derivative with antibacterial activity | SHIONOGI & CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6218550-B1 | MANUFACTURING (2S,4S)-2-(((R)-HYDROXY-(3R)-CYCLIC AMINE-3-YL)METHYL)PYRROLIDINE-4-THIOL OR A SALT THEREOF | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1020440-A1 | INTERMEDIATES USEFUL IN PRODUCING CARBAPENEM AND PROCESS FOR THE STEREOSELECTIVE PRODUCTION OF THE SAME | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5703243-A | Intermediates for pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-12-30 | — | — | US | disclosed |
| US-5317016-A | Pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-05-31 | — | — | US | disclosed |
| EP-0528678-A1 | A pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213809-A1 | Coenzyme substrates; kits; nicotinamide adenine dinucleotide; biochemical detection | NQO1, NADK, NAMPT | NR1H2 2499/4885SRC 4581/4885CHRM2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.